Positive Phase III Results for Narcolepsy Drug with Low Cardiovascular Risk
The narcolepsy drug, developed by Irish company Jazz Pharmaceuticals, has a lower salt content than the current treatment Xyrem, making it more suitable for patients at risk of cardiovascular disease. In a 200-patient phase III trial that finished in July, Jazz
French medtech startup Robocath raises €5 million for its cardiovascular robotic systems
Rouen-based medtech startup Robocath designs, develops, and commercializes cardiovascular robotic systems for the treatment of vascular diseases such as heart attack and stroke. The startup has raised €5 million to support the rollout of its robotic platform in strategic European